Literature DB >> 11981336

Serological differentiation of inflammatory bowel diseases.

Karsten Conrad1, Helmut Schmechta, Agnes Klafki, Gunhild Lobeck, Holm H Uhlig, Suhail Gerdi, Jobst Henker.   

Abstract

OBJECTIVE: In order to shorten the diagnostic procedures simple serological tests with high diagnostic value for Crohn's disease and ulcerative colitis are required. The aim of this study was therefore to evaluate the diagnostic value of a newly developed assay for the determination of antibodies to mannan of Saccharomyces cerevisiae in combination with antibodies to antigens of exocrine pancreas, goblet cells, human neutrophils and tissue transglutaminase.
METHODS: Sera from 112 patients with Crohn's disease (82 confirmed and 30 suspected cases), 65 patients with ulcerative colitis, 13 patients with indeterminate colitis, 212 patients with other diseases and 250 healthy blood donors were tested for IgA and IgG antibodies to mannan of S. cerevisiae and IgA to tissue transglutaminase by enzyme-linked immunoassays. Endomysial IgA antibodies and antibodies to antigens of exocrine pancreas, goblet cells and human neutrophils were determined by indirect immunofluorescence. Sensitivity, specificity, positive and negative predictive values of antibodies to mannan of S. cerevisiae and different antibody combinations were determined regarding the diagnosis of Crohn's disease and ulcerative colitis.
RESULTS: Antibodies to mannan of S. cerevisiae were detected in 50% of confirmed and 27% of patients suspected of having Crohn's disease. Among patients who did not have Crohn's disease only those suffering from gluten-sensitive enteropathy and primary biliary cirrhosis exhibited antibodies to mannan of S. cerevisiae (14%, 6%). With respect to antibody positivity, antibodies to mannan of S. cerevisiae and/or antibodies to antigens of exocrine pancreas combined with tissue transglutaminase antibody negativity yields a sensitivity, specificity, positive and negative predictive value of 60%, 100%, 100% and 90%, respectively, regarding diagnosis of Crohn's disease.
CONCLUSIONS: Determination of antibodies to mannan of S. cerevisiae as a new marker for Crohn's disease is helpful for the differential diagnosis of inflammatory bowel disease. In combination with other established serological markers, antibodies to mannan of S. cerevisiae improve their diagnostic and predictive values considerably.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981336     DOI: 10.1097/00042737-200202000-00006

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  8 in total

1.  Pancreatic autoantibodies in Greek patients with inflammatory bowel disease.

Authors:  Ioannis E Koutroubakis; Dimitrios Drygiannakis; Konstantinos Karmiris; Ioannis Drygiannakis; Sokratis Makreas; Elias A Kouroumalis
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

2.  A new model for the discrimination between ulcerative colitis and Crohn's disease.

Authors:  Zhe Shen; Wei-Ping Ma; Xiao-Na Shao; Chao-Hui Yu; Juan Du; Zun Xiang; Gan-Hua Guo; Hong Zhang; You-Ming Li; Min Yue
Journal:  Int J Clin Exp Med       Date:  2015-01-15

3.  Anti-pancreatic antibody in Turkish patients with inflammatory bowel disease and first-degree relatives.

Authors:  Huseyin Demirsoy; Kamil Ozdil; Ozdal Ersoy; Besir Kesici; Cetin Karaca; Canan Alkim; Nihat Akbayir; Levent Kamil Erdem; Mehmet Derya Onuk; Hulya Tugrul Beyzadeoglu
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

4.  Loss and Gain of Tolerance to Pancreatic Glycoprotein 2 in Celiac Disease.

Authors:  Martin W Laass; Nadja Röber; Ursula Range; Lydia Noß; Dirk Roggenbuck; Karsten Conrad
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

5.  Pancreatic-specific autoantibodies to glycoprotein 2 mirror disease location and behaviour in younger patients with Crohn's disease.

Authors:  Dimitrios P Bogdanos; Dirk Roggenbuck; Dirk Reinhold; Thomas Wex; Polychronis Pavlidis; Ulrike von Arnim; Peter Malfertheiner; Alastair Forbes; Karsten Conrad; Martin W Laass
Journal:  BMC Gastroenterol       Date:  2012-08-06       Impact factor: 3.067

6.  The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.

Authors:  Valentina Somma; Hani Ababneh; Ahmad Ababneh; Simona Gatti; Vittorio Romagnoli; Emanuele Bendia; Karsten Conrad; Dimitrios P Bogdanos; Dirk Roggenbuck; Gino Ciarrocchi
Journal:  Gastroenterol Res Pract       Date:  2013-05-15       Impact factor: 2.260

7.  Automated interpretation of ANCA patterns - a new approach in the serology of ANCA-associated vasculitis.

Authors:  Ilka Knütter; Rico Hiemann; Therese Brumma; Thomas Büttner; Kai Großmann; Marco Cusini; Francesca Pregnolato; Maria Orietta Borghi; Ursula Anderer; Karsten Conrad; Dirk Reinhold; Dirk Roggenbuck; Elena Csernok
Journal:  Arthritis Res Ther       Date:  2012-12-14       Impact factor: 5.156

Review 8.  CUZD1 and anti-CUZD1 antibodies as markers of cancer and inflammatory bowel diseases.

Authors:  Christos Liaskos; Eirini I Rigopoulou; Timoklia Orfanidou; Dimitrios P Bogdanos; Christos N Papandreou
Journal:  Clin Dev Immunol       Date:  2013-04-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.